Navigation Links
Biosimilar Insulins and Insulin Analogues Stand to Erode $6.1 Billion in Brand Sales in the U.S. and Europe by 2018
Date:10/14/2009

WALTHAM, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilar insulins and insulin analogues stand to erode $6.1 billion in brand sales in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018, saving healthcare systems $3.8 billion in the process.

As insulins are relatively easy to develop and manufacture, the new special report entitled Biosimilars: ESAs, Insulins, and Human Growth Hormones, predicts that a number of competing long-acting biosimilar insulins, which are typically injected once or twice daily, will enter the market during the 2008-2018 study period. Based on differences in revenue and upon patent expiry, Sanofi-Aventis' Lantus presents a greater opportunity for manufacturers of biosimilars than Novo-Nordisk's Levemir.

"Our survey data suggests that most endocrinologists expect to begin prescribing biosimilars within a year after they launch. Although endocrinologists will require a fair amount of clinical data before they will be comfortable prescribing biosimilars, they have fewer reservations about using biosimilar insulins (used in patients with diabetes) than they do for biosimilar human growth hormones (used in patients with human growth hormone deficiency)," stated MaryEllen Klusacek, Ph.D., analyst at Decision Resources.

The report also finds that although surveyed nephrologists have an overall conservative attitude towards biosimilar use, they are not completely opposed to prescribing a biosimilar for an indication in which it has been approved, but not clinically studied. Based on EMEA guidelines and proposed legislation in the United States, biosimilars will be labeled for each indication for which the reference product is labeled, even if the biosimilar is only clinically studied in one indication. For example, while Johnson & Johnson's Procri
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
2. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
3. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
4. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
5. Epidemics of Both Type 1 Diabetes (Insulin Dependent) and Type 2 Diabetes (Obesity Related) Are Linked to Immunization
6. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
7. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
8. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
9. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
10. Modified Insulin Most Effective For Controlling Post-Meal Blood Sugar Levels
11. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... -- According to a new market research report ... Cord Stimulation, Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, Tinnitus, Alzheimer,s, ... by MarketsandMarkets, the global Neuromodulation Market is estimated at $3.65 ... by 2020, at a CAGR of 11.2% during the forecast ... market data T ables and ...
(Date:7/2/2015)... July 2, 2015   EVO Aesthetic Center and ... provider for non-invasive aesthetics in Lakeway, Texas ... treatments with the Astanza Duality laser. The medical spa ... through various medical and laser procedures. Their addition of ... a clear solution to their tattoo regret. ...
(Date:7/2/2015)... July 2, 2015 Pharma Major Lupin ... ZAO "Biocom" in Russia subject to ... Russian pharmaceutical market which recorded RUB 765 billion in sales, ... in the world in 2014 (IMS Health). For over a ... to continue with this trend, projecting Russia ...
Breaking Medicine Technology:Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Lupin Acquires Biocom in Russia 2Lupin Acquires Biocom in Russia 3
... 21, 2011 Robbins Umeda LLP, a shareholder ... possible breaches of fiduciary duty and other violations of ... Pharmaceutical Company (NYSE: KV-A, KV-B). (Logo: ... focuses on whether officials at KV Pharmaceuticals breached their ...
... the vaccines division of Sanofi (EURONEXT: SAN and NYSE: ... a new study evaluating the immunogenicity and safety of ... 65 years of age and older. Currently licensed influenza ... circulate in a given year. The data were presented ...
Cached Medicine Technology:Robbins Umeda LLP Announces an Investigation of KV Pharmaceutical Company 2Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 2Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 3Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 4Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 5
(Date:7/2/2015)... ... 2015 , ... Five individuals from Loma Linda University Health ... disaster training. The team – composed of four clinicians and one administrative staff ... attended the training, which is dedicated to preparing first responders for a mass ...
(Date:7/2/2015)... ... ... Hand sanitizers have become extremely popular with an annual industry growth rate ... and radio host Sharon Kleyne, hand sanitizers can effectively decrease the presence of disease ... must be applied correctly and users must be aware of its limitations. , ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... healthcare providers, has been retained to lead a national chief operating officer ... executive search firms in the healthcare industry, B. E. Smith has recently placed ...
(Date:7/2/2015)... ... , ... Throughout the month of April, Casey’s General Stores invited customers to ... July 7, Casey’s General Stores Chairman and CEO, Bob Myers, will present a check ... national nonprofit dedicated to restoring a sense of self, restoring the family unit, and ...
(Date:7/2/2015)... Arlington, VA (PRWEB) , ... July 02, 2015 , ... ... the enabler of enterprise collaboration across platforms and devices, today announced it was ... SaaS for its Citizen Connect Platform. The award, given out by the Government Technology ...
Breaking Medicine News(10 mins):Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 2Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 3Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 2Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 2Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 4
... slight elevation was linked to coronary artery calcification in study ... of phosphorus are associated with a higher risk of heart ... phosphorus levels and coronary artery calcification (CAC) in nearly 900 ... of heart disease risk factors. CAC is an early sign ...
... The Cornea and Laser Eye Institute is participating in a ... safely and effectively reduce the need for reading glasses. ... , The investigational AcuFocus Corneal Inlay (ACI) ... which is the loss of near vision, and reduce dependency ...
... FreedomVOICE® proposes ... and offers tips to business owners to develop a work at home policy. , ... Encinitas, CA (Vocus) -- FreedomVOICE®, creators of the ... of the H1N1 virus in the workplace., , ,Whether we like it or not, the H1N1 ...
... DIEGO, Nov. 5 Volcano Corporation (Nasdaq: VOLC ), ... for the diagnosis and treatment of coronary and peripheral artery ... quarter of fiscal 2009. , The results for the quarter ... over revenues of $44.1 million in the third quarter of ...
... aid understanding of human diseases, scientists say , THURSDAY, ... domestic horse has been sequenced, an accomplishment that will ... of human health, according to an international team of ... it easier to understand all genomes, including our own. ...
... A drug already approved for the treatment of lymphoma may ... in children and teens, according to an early-stage study published ... The study drug, Bortezomib, was found to be effective against ... While key experiments were in animals, the cancer studied closely ...
Cached Medicine News:Health News:Phosphorus Levels May Predict Heart Disease 2Health News:Near vision research study 2Health News:FreedomVOICE Proposes Telecommuting to Tackle the H1N1 Virus 2Health News:FreedomVOICE Proposes Telecommuting to Tackle the H1N1 Virus 3Health News:FreedomVOICE Proposes Telecommuting to Tackle the H1N1 Virus 4Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 2Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 3Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 4Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 5Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 6Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 7Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 8Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 9Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 10Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 11Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 12Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 13Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 14Health News:Complete Horse Genome Sequence Revealed 2Health News:Approved lymphoma drug shows promise in early tests against bone cancer 2
... The COMPACT Portable II A/B ... images close to analog quality. ... simply nothing like it. Keep ... system or take it to ...
The ultimate ultrasound system for clinical ophthalmologists....
... Eye care in the ... and flexibility. The Alcon® UltraScan® ... multifunction system targeted at clinical ... Biometry. Easy-to-use software, permits step-by-step ...
... Micro-Incision Cataract Surgery (MICS) Is ... unique double-step hexagonal shape, the ... for MICS. The consistently sharp-edged ... allow you to obtain accurate ...
Medicine Products: